Cigna sits at the hinge between two business models. The rebate-free PBM transition begins to touch P&L in 2027, the CEO handoff closes July 1, 2026, and the 2026 MCR guide (83.7%–84.7%) has to hold. The next three quarterly prints are the cleanest windows into whether the "clearing events" story is real or a disguised earnings air pocket.
Loading...
No Results
The single item the market will watch most closely is the Q2 2026 print under Evanko: first report from the new CEO, first real test of the reaffirmed $30.25 adj EPS floor, and the first look at how large clients are renewing into the rebate-free framework for 2027. A clean beat with MCR inside the 83.7%–84.7% guide probably re-rates the name toward peers. A soft MCR or a walk-down of the Evernorth margin narrative does not.
Explicitly not catalysts worth waiting on: macro rate moves, sector-wide MA rate notices (CI is out of MA), and legacy VillageMD headlines (already impaired).
**Earnings power is intact while the multiple is not.** Adjusted EPS compounded $20.47 → $29.85 from FY21–FY25 (~10% CAGR) with a guide-beat every year (Historian). Yet the stock trades at 9.3x trailing vs 12x historical and 15.8x for UNH (Quant). At 12x FY25 adj EPS the stock re-rates to ~$358.
**FCF per share is the real compounding engine.** $8.4B FCF on a $74B cap is an ~11% FCF yield; the share count fell 23% since FY21 to 263M, pushing FCF per share to $31.80 (Quant). Buybacks plus ~9% dividend growth can deliver high-single-digit total return even if operating income merely plateaus.
**The regulatory overhang cleared in February 2026.** FTC settlement closed without a monetary penalty; top-3 Evernorth clients (Centene, Prime, DoD) are renewed through end of decade; Medicare Advantage divestiture is done (Historian, Research). Most of the "break the thesis" tail risks have actually broken the other way.
**Evernorth rides a structural tailwind the market is not pricing.** ~$100B of specialty drug spend faces biosimilar and generic competition over five years; Accredo specialty scripts grew 13% YoY; Shields Health Solutions ($3.5B) deepens hospital-based specialty pharmacy capacity (Warren, Research). This is the part of the mix genuinely growing, not pass-through inflating.
**The Evernorth margin is going the wrong way.** Pre-tax margin compressed 4.2% → 3.5% → 3.1% across FY23–FY25, before the rebate-free rollout even touches the P&L. Major 2025 renewals closed at lower margins and TD Cowen cut its target $387 → $333 (Warren, Research). If margin stabilizes below 2.5% through 2027, the $44.9B Express Scripts goodwill is in economic substance impaired.
**MCR keeps drifting higher.** Medical care ratio 78.8% → 81.3% → 83.2% → 84.4% across FY22–FY25 driven by IFP and stop-loss (Warren, Historian). The 2026 guide of 83.7%–84.7% assumes the drift stops — it has not stopped in three years.
**Concentration is real and under-appreciated.** A single pharmacy client (likely Centene) drove ~19% of 2025 external revenue and the top three clients drive roughly 60% of Evernorth profits. Renewals are locked through 2029, but one non-renewal at decade-end rewrites the model (Warren, Research).
**The GAAP-to-adjusted gap is structural, not episodic.** Average $3.2B annual gap across FY21–FY25; VillageMD ($2.7B) was written down inside "special items," not flagged in advance (Historian). The standalone compliance committee was dissolved while the HHS-OIG Corporate Integrity Agreement still runs through 2028 (Sherlock). Insiders own 1.44% and have not stepped in at these prices.
I'd lean cautiously constructive here — slight edge to the For side, but soft. The item that tips the scale is the FCF-per-share math: at 8.7x FCF per share with a 23% share count reduction already delivered and $10.3B of buyback authorization left, you do not need Evernorth margin to expand for a total-return thesis to work at this price. The Against side's strongest punch is the MCR drift, and that is a genuine thing to watch, not dismiss. I would wait for the Q2 2026 print under Evanko before sizing anything up; if MCR prints inside the 83.7%–84.7% guide and management reaffirms the $30.25 adj EPS floor, the rebate-free story becomes "transition not impairment" and the discount to UNH can close meaningfully. The one condition that would flip me to cautious-against: an Evernorth pre-tax margin print below 2.8% paired with management walking down the 10–14% long-term EPS algorithm — because at that point the Express Scripts goodwill is impaired in economic substance, even if not yet on the balance sheet.